MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/250/0.02/20.09.24

MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/250/0.02/20.09.24 Share Price

DE000ME9H221

Real-time Bid/Ask 16:29:31 16/07/2024 BST
0.9 ^EUR / 0.99 ^EUR	+8.62%

Current month	-6.45%
1 month	-5.43%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MADRIGAL PHARMACEUTICALS, INC.

Chart MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/250/0.02/20.09.24

Latest news about MADRIGAL PHARMACEUTICALS, INC.

JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating	04:17pm	MT
Non Alcoholic Fatty Liver Disease Pipeline 2024 \| Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceutical	07-10	AQ
Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating	06-28	MT
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	06-11

More news

Quotes 5-day view

Date	Price	Change
16/07/24	0.9	+3.45%
15/07/24	0.87	-11.22%
12/07/24	0.98	-7.55%
11/07/24	1.06	+0.95%
10/07/24	1.05	-4.55%

Delayed Quote Börse Stuttgart

Last update July 16, 2024 at 12:59 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	MADRIGAL PHARMACEUTICALS, INC.
Issuer	Morgan Stanley
WKN	ME9H22
ISIN	DE000ME9H221
Date issued	01/03/2024
Strike	250 $
Maturity	20/09/2024 (66 Days)
Parity	50 : 1
Emission price	1.24 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.73 €
Lowest since issue	0.22 €
Delta	0.73x
Omega	3.718
Premium	7.1x
Gearing	5.1x
Moneyness	1.143
Difference Strike	-29.2 $
Difference Strike %	-11.68%
Spread	0.1 €
Spread %	9.26%
Theoretical value	0.9700
Implied Volatility	76.76 %
Total Loss Probability	41.54 %
Intrinsic value	0.5517
Present value	0.4183
Break even	302.78 €
Theta	-0.03x
Vega	0.01x
Rho	0x

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Sector

More about the company

Consensus: Madrigal Pharmaceuticals, Inc.

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

280 USD

Average target price

365.3 USD

Spread / Average Target

+30.50%

Consensus